Adicet Bio Management

Management Kriterienprüfungen 2/4

Adicet Bio CEO ist Chen Schor , ernannt in Sep 2020, hat eine Amtszeit von 4.17 Jahren. Die jährliche Gesamtvergütung beträgt $5.97M , bestehend aus 10.1% Gehalt und 89.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.16% der Aktien des Unternehmens, im Wert von $141.64K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.1 Jahre bzw. 3.5 Jahre.

Wichtige Informationen

Chen Schor

Geschäftsführender

US$6.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	10.1%
Amtszeit als Geschäftsführer	4.2yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	4.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Jul 12

Adicet Bio: Microcap With A High Risk To Reward Ratio

May 23

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chen Schor im Vergleich zu den Einnahmen von Adicet Bio verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$118m
Jun 30 2024	n/a	n/a	-US$137m
Mar 31 2024	n/a	n/a	-US$140m
Dec 31 2023	n/a	n/a	-US$143m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$4m	US$562k	-US$70m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$10m	US$536k	-US$62m
Sep 30 2021	n/a	n/a	-US$55m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$11m	US$499k	-US$37m

Vergütung im Vergleich zum Markt: ChenDie Gesamtvergütung ($USD5.97M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD650.40K).

Entschädigung vs. Einkommen: ChenDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Chen Schor (52 yo)

4.2yrs

Amtszeit

US$5,973,807

Vergütung

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Chen Schor	CEO, President & Director	4.2yrs	US$5.97m	0.16% $ 141.6k
Aya Jakobovits	Founder & Independent Director	no data	US$240.29k	1.04% $ 899.5k
Brian Harvey	Chief Financial Officer	4.2yrs	US$2.13m	0.068% $ 58.9k
Donald Healey	Chief Technology Officer	4.1yrs	US$2.09m	0.043% $ 37.0k
Blake Aftab	Senior VP & Chief Scientific Officer	3.6yrs	US$2.48m	0.031% $ 26.7k
Amy Locke	Chief Human Resource Officer	2.8yrs	keine Daten	keine Daten
Francesco Galimi	Chief Medical Officer & Senior VP	4.2yrs	US$1.99m	0.092% $ 79.3k
Nancy Boman	Senior VP & Chief Regulatory Officer	2yrs	keine Daten	keine Daten

4.1yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: ACETDas Führungsteam des Unternehmens gilt als erfahren (4.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Chen Schor	CEO, President & Director	4.2yrs	US$5.97m	0.16% $ 141.6k
Aya Jakobovits	Founder & Independent Director	4.2yrs	US$240.29k	1.04% $ 899.5k
Carl Gordon	Independent Chairman	4.2yrs	US$275.29k	0.0072% $ 6.2k
Steve Dubin	Independent Director	4.2yrs	US$254.29k	0.013% $ 11.4k
Andrew Sinclair	Independent Director	3.7yrs	US$255.29k	0.0072% $ 6.2k
Jeffrey Chodakewitz	Independent Director	4.2yrs	US$240.29k	0.0072% $ 6.2k
Marco Davila	Member of Scientific Advisory Board	3.3yrs	keine Daten	keine Daten
Lloyd Klickstein	Director	less than a year	US$2.90m	0.12% $ 107.8k
Michael Kalos	Member of Scientific Advisory Board	3.3yrs	keine Daten	keine Daten
Saul Priceman	Member of Scientific Advisory Board	3.3yrs	keine Daten	keine Daten
Constantine Mitsiades	Member of Scientific Advisory Board	3.3yrs	keine Daten	keine Daten
Alice Bertaina	Member of Scientific Advisory Board	3.3yrs	keine Daten	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: ACETDie Vorstandsmitglieder gelten als erfahren (3.5 Jahre durchschnittliche Amtszeit).

Adicet Bio Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

Chief Technology Officer notifies of intention to sell stock

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

Recent updates

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio: Microcap With A High Risk To Reward Ratio

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Price target decreased by 18% to US$12.80

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Price target decreased by 15% to US$18.29

New minor risk - Market cap size

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Price target decreased by 14% to US$23.29

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 180%, EPS downgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Chief Technology Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Consensus forecasts updated

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

CEO, President & Director notifies of intention to sell stock

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Now 23% undervalued after recent price drop

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Adicet Bio: A First Take

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

Consensus revenue estimates increase by 42%

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

High number of new and inexperienced directors

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Chief Medical Officer & Senior VP notifies of intention to sell stock

Consensus forecasts updated

Consensus revenue estimates fall by 31%

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Full year 2021 earnings: EPS and revenues exceed analyst expectations